几乎有一半(40 %)，与会者以一个以上的抗胆碱药物。
Almost half (40 percent) of participants were taking more than one anticholinergic drug.
在慢性阻塞性肺疾病(COPD)的维持治疗方面，使用长效抗胆碱药物作为基础治疗与国家和国际的有关指南相符合。
As maintenance treatment for COPD, basic treatment with long-acting anticholinergics accords with both national and international guidelines.
如果你是老年人，这些被称之为抗胆碱能类的药物会使你大脑模糊，记忆减退。
If you're elderly, these drugs, called anticholinergics, can cause mental fogginess and forgetfulness.
这类药物应用非常广泛，但其抗胆碱能和镇静作用却很难被患者所耐受。
These medications are widely used but their anticholinergic and sedative properties may not be well tolerated by patients.
这些药物被称为抗胆碱能制剂和旨在阻止乙酰胆碱。
These drugs are known as anticholinergic agents and are designed to block acetylcholine.
结果发现，年龄、性别、抗胆碱能药物、用药总时间和目前用药量等五个因素在0.05或0.01水平上对TES的存在有显著意义上的作用。
It was found suggest that age, gender, anticholinergic drugs, treatment duration and current dosage as the risk factors have significant effects on the existence of TES at 0.05 or 0.01 level.
血管内皮细胞乙酰胆碱作用靶标(ETA)作为特异性血管内皮细胞药物作用新靶点具有良好的抗动脉粥样硬化应用前景。
Endothelial target for acetylcholine (ETA) plays an important role in preventing atherosclerosis, and it may be a unique molecular target of the novel drugs against atherosclerosis.
新型选择性抗胆碱能药物作为支气管扩张剂在COPD治疗中发挥了重要的作用。
As bronchodilators, new type selective anticholinergics play an important role in the treatment of COPD.
羟基-9-呫吨羧酸甲酯是合成呫吨类抗胆碱能药物的一种重要的中间体。
Methyl 9-hydroxyl-9-xanthene carboxyate which is an important intermediate of xanthene anticholiergic drugs was easily synthesized from methyl 9-xanthene carboxyate.
目的：评价抗胆碱能类药物和茶碱制剂以及祛痰药的临床应用情况。
OBJECTIVE: to analyze the status quo of the current application of expectorants so as to provide references for rational use of drugs in the clinic.
抗胆碱酯类药物可刺激神经脉冲传送，皮质类固醇也有帮助。
Anticholinesterase drugs stimulate nerve-impulse transmission, and corticosteroids may help.
文献纳入规范研究吸入抗胆碱能药物疗治COPD的随机对照试验，药物疗治时间不少于30天，而且报道有心思和精力管不良事件。
Study Selection Randomized controlled trials of any inhaled anticholinergic for treatment of COPD that had at least 30 days of treatment and reported on cardiovascular events.
结论COPD患者吸入抗胆碱能药物与发生心血管死亡，心肌梗死或卒中风险增高有关。
Conclusion Inhaled anticholinergics are associated with a significantly increased risk of cardiovascular death, MI, or stroke among patients with COPD.
目的明确吸入抗胆碱能药物发生心血管不良反应(包括心血管病死亡，心肌梗死以及卒中)的危害。
Objective To ascertain the cardiovascular risks of inhaled anticholinergics, including cardiovascular death, myocardial infarction (MI), and stroke.
研究和开发相关抗炎药物和电刺激、针刺穴位等抗炎手段已经成为将胆碱能抗炎通路应用于临床的有益尝试。
It is beneficial to experiment relatively with anti-inflammatory drugs and new methods, such as vagus nerve stimulation and acupuncture.
研究和开发相关抗炎药物和电刺激、针刺穴位等抗炎手段已经成为将胆碱能抗炎通路应用于临床的有益尝试。
It is beneficial to experiment relatively with anti-inflammatory drugs and new methods, such as vagus nerve stimulation and acupuncture.
应用推荐